Millennium reports 3.38M-share passive stake in Vanda (NASDAQ: VNDA)
Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have reported a collective passive stake of 3,376,401 shares in Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), representing 5.6% of the outstanding common stock. They hold shared voting and dispositive power over these shares, indicating a joint investment approach rather than sole control. The filing clarifies that while the entities are subject to their voting control and investment discretion, this should not be construed as an admission of beneficial ownership for legal and reporting purposes.
AIGH Capital Management LLC Purchases New Stake in Vanda Pharmaceuticals Inc. $VNDA
AIGH Capital Management LLC has acquired a new stake of over 2 million shares in Vanda Pharmaceuticals Inc., valued at approximately $12.5 million, making it their 21st largest position. Analyst sentiment for Vanda Pharmaceuticals is mixed but leans positive, with a "Moderate Buy" consensus rating and a $13.70 average price target. Despite this, the company recently missed analyst estimates for both earnings per share and revenue in its latest quarterly report.
Monaco Asset Management SAM Invests $1.35 Million in Vanda Pharmaceuticals Inc. $VNDA
Monaco Asset Management SAM has acquired a new stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), purchasing 221,286 shares valued at approximately $1.35 million. This investment makes Vanda Pharmaceuticals 0.1% of Monaco Asset Management SAM's portfolio and represents about 0.37% ownership of the company. The biopharmaceutical company recently reported weaker-than-expected quarterly earnings, missing analyst estimates for both EPS and revenue.
Vanda Prepares BYSANTI Launch As Patent Protection Extends To 2044
Vanda Pharmaceuticals is set to launch BYSANTI in the second half of 2026 following FDA approval for bipolar I disorder and schizophrenia, with patent protection extending until May 2044. The company also reported strong Q2 Fanapt sales growth and has several late-stage pipeline readouts expected by year-end 2026, including for NEREUS, VQW-765, and HETLIOZ. Vanda anticipates its current resources and product revenue will fund operations through at least the end of 2027, with operating expenses expected to decline starting in late 2026.
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Given Consensus Rating of "Moderate Buy" by Brokerages
Vanda Pharmaceuticals (NASDAQ:VNDA) has received a consensus "Moderate Buy" rating from eight brokerages, with an average 12-month price target of $13.70 despite recent reductions from some analysts. The company reported a larger-than-expected quarterly loss and missed revenue estimates, leading analysts to anticipate unprofitability for the current fiscal year. Despite this, institutional ownership remains high, with major firms increasing their stakes, while the stock trades significantly below its 12-month high.
AQR Capital discloses 5.82% Vanda Pharmaceuticals (VNDA) ownership on 13G
AQR Capital Management, LLC and AQR Capital Management Holdings, LLC have disclosed a passive ownership stake of 5.82% in Vanda Pharmaceuticals Inc. (VNDA), amounting to 3,497,695 shares. The SEC filing, a Schedule 13G, indicates that these entities have shared voting power over 3,313,298 shares and shared dispositive power over all 3,497,695 shares. This disclosure highlights AQR's significant but passive investment in the pharmaceutical company.
Q3 EPS Estimate for Vanda Pharmaceuticals Cut by Analyst
HC Wainwright has significantly cut its Q3 2026 EPS estimate for Vanda Pharmaceuticals (NASDAQ: VNDA) to a loss of $0.61, down from $0.36, and projects a full-year 2026 loss of $3.03 per share, indicating deeper expected losses. This follows Vanda's recent miss on quarterly expectations, reporting a $1.04-per-share loss against a $0.58 consensus and lower-than-expected revenue. Despite these lowered estimates, HC Wainwright maintained a "Buy" rating with a $20 target, while other analysts have a "Moderate Buy" consensus rating with a $13.70 target.
B. Riley Adjusts Vanda Pharmaceuticals Price Target to $12 From $17, Maintains Buy Rating
B. Riley has adjusted its price target for Vanda Pharmaceuticals to $12 from $17, while reiterating a "Buy" rating for the company. This news comes amidst other recent updates for Vanda, including their Q2 2026 earnings call, revenue guidance reiteration, and reports of positive opinions and designations for their investigational therapies. The article also provides an overview of Vanda Pharmaceuticals' commercial portfolio and pipeline.
Dimensional Fund Advisors LP Lowers Holdings in Vanda Pharmaceuticals Inc. $VNDA
Dimensional Fund Advisors LP reduced its stake in Vanda Pharmaceuticals (NASDAQ:VNDA) by 16.4% in the first quarter, selling 346,835 shares but still holding 1.77 million shares valued at $12.24 million. The biopharmaceutical company reported weaker-than-expected Q1 results, with an adjusted loss of $1.04 per share and revenue of $50.53 million, both missing analyst estimates. Despite these results and the stock opening near its 52-week low, analysts maintain a "Moderate Buy" rating with a consensus price target of $14.30.
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Just Reported Earnings, And Analysts Cut Their Target Price
Vanda Pharmaceuticals Inc. recently reported disappointing second-quarter results, with revenues falling 18% short of analyst estimates and statutory losses exceeding expectations. Following this, analysts have downgraded revenue forecasts, increased projected per-share losses, and cut the consensus price target by 12% to US$12.44, reflecting concerns about the company's future valuation despite expectations for faster revenue growth than the broader industry.
Vanda Posts Wider Q2 Loss as Spending Surges; Revenue Dips 4% on Hetlioz Decline
Vanda Pharmaceuticals reported a wider second-quarter 2026 net loss of $62.5 million, up from $27.2 million a year prior, as operating expenses surged to $114.3 million. Revenue declined 4% to $50.5 million, primarily due to a 66% drop in Hetlioz sales, while Fanapt sales rose 23%. The company reiterated its full-year revenue guidance and anticipates moderating expenses and key product launches, including BYSANTI and a December FDA decision for Quimilza.
Vanda Pharmaceuticals Inc. (VNDA) stock price, news, quote and history
This Yahoo Finance page provides comprehensive information on Vanda Pharmaceuticals Inc. (VNDA), including its current stock price, recent news, financial statistics, and historical data. It details the company's product portfolio and pipeline, financial performance metrics, analyst ratings, and comparisons with similar biotechnology companies. The stock closed at $5.12, showing a slight increase from its previous close, and has a market cap of $309.267M.
Earnings call transcript: Vanda misses Q2 2026 estimates as losses widen
Vanda Pharmaceuticals reported a wider-than-expected loss and lower-than-forecast revenue for Q2 2026, driven by a sharp decline in HETLIOZ sales despite growth in Fanapt and PONVORY. The company missed analyst estimates with an adjusted loss of $1.04 per share on revenue of $50.5 million, but reiterated its full-year revenue guidance and pointed to several upcoming clinical and regulatory catalysts. Vanda also expects operating expenses to moderate in late 2026 and 2027 and believes it has sufficient cash to fund operations through at least the end of 2027.
Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results
Vanda Pharmaceuticals announced its second quarter 2026 financial results, highlighting a 23% increase in Fanapt® net product sales to $36.0 million and forecasting full-year 2026 total revenue between $240-$290 million. The company reported a cash balance of $170.0 million, expected to fund operations through at least 2027, and provided updates on recent FDA approvals, ongoing regulatory reviews, and upcoming clinical trial results for several key products, including BYSANTI™ and Quimilza™. Despite significant investments in new product launches leading to a net loss of $62.5 million for the quarter, Vanda anticipates operating expenses to moderate later in 2026 and more substantially in 2027.
Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Lags Revenue Estimates
Vanda Pharmaceuticals (VNDA) reported a Q2 loss of $1.04 per share, significantly missing the Zacks Consensus Estimate of a $0.51 loss, and also lagged revenue estimates with $50.53 million against an expected $62.67 million. The company's shares have fallen almost 40% year-to-date, and its Zacks Rank of #3 (Hold) suggests it will perform in line with the market. Another industry peer, Prothena (PRTA), is expected to report its Q2 results soon.
Vanda Pharmaceuticals Inc expected to post a loss of 59 cents a share - Earnings Preview
Vanda Pharmaceuticals Inc is projected to report a loss of 59 cents per share. This information is part of an earnings preview. The full article by Refinitiv is available on TradingView.
Vanda Pharmaceuticals Number of Employees 2026 | Employee Count & Headcount Data
Vanda Pharmaceuticals (NASDAQ: VNDA) had 561 employees worldwide as of March 2026, marking a 107.9% growth since 2023. The company is actively hiring, with 218 active job postings in 2026, and its workforce is primarily concentrated in North America, with Engineering being the largest and fastest-growing functional group. The average salary at Vanda Pharmaceuticals is $128,702.
Vanda investors can hear its Q2 update Aug. 5 at 4:30 p.m.
Vanda Pharmaceuticals (Nasdaq: VNDA) is scheduled to release its second-quarter 2026 financial results on Wednesday, August 5, 2026, after market close. The company will host a conference call and webcast at 4:30 PM ET on the same day to discuss the results and corporate activities. Investors can access the call via phone or Vanda's website, with a replay available until August 12, 2026.
Vanda Pharma (VNDA.US) Stock Price, Quote & News
This article provides an overview of Vanda Pharmaceuticals Inc. (VNDA.US) stock information, including its current price ($5.050), daily performance, and trading metrics. It also presents analyst ratings with a price forecast of $14.13 and a "Buy" consensus, along with recent news updates pertaining to the company's financial results, sponsorships, and FDA designations.
Vanda Pharmaceuticals Inc (VNDA) Institutional Confidence
Vanda Pharmaceuticals Inc (VNDA) has an institutional shareholding score of 7.00, placing it 80th out of 385 in the Biotechnology & Medical Research industry. The institutional shareholding proportion has increased by 1.13% quarter-over-quarter to 78.40%, with James Simons being the largest institutional shareholder holding 6.25% of outstanding shares. Major institutional holders include BlackRock Institutional Trust Company, Renaissance Technologies LLC, and State Street Investment Management (US).
Vanda Pharmaceuticals Inc (VNDA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for Vanda Pharmaceuticals Inc (VNDA), highlighting its business segments and regional contributions. The data, updated on April 6, shows that the company's revenue is primarily driven by products such as Fanapt, Hetlioz, and PONVORY, with all revenue currently originating from the United States. It includes financial figures for fiscal years up to 2025.
VNDA|Vanda Pharmaceuticals Inc|Price:5.280|Chg%:+0.100
This article provides a comprehensive stock analysis of Vanda Pharmaceuticals Inc (VNDA) using TradingKey's stock score. It highlights the company's stable fundamentals, high growth potential, and fair valuation which ranks 78th in the Biotechnology & Medical Research industry. Despite recent weak stock market performance, VNDA shows strong fundamentals and is seen as suitable for range-bound swing trading with multiple analysts rating it as a "Buy" and a target price of 14.12.
Vanda Pharmaceuticals Inc (VNDA) Valuation: PE, PB & Fair Value Analysis
Vanda Pharmaceuticals Inc (VNDA) currently holds a valuation score of 7.67, positioning it 208th out of 386 companies in the Biotechnology & Medical Research industry. The company's P/E ratio is -1.32, which is significantly below its recent high and above its recent low. Key valuation metrics like P/B, P/S, and P/CF have not yet been disclosed by the company.
B. Riley Securities Maintains Vanda Pharmaceuticals(VNDA.US) With Buy Rating, Maintains Target Price $17
B. Riley Securities has reiterated its Buy rating for Vanda Pharmaceuticals (VNDA.US), maintaining its target price at $17. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.
ETFs Investing in Vanda Pharmaceuticals Inc. Stocks
This article lists various ETFs that hold Vanda Pharmaceuticals Inc. (VNDA) stocks, providing detailed financial information for each fund. The data includes market value, weight of VNDA in the fund, issuer, management style, focus, expense ratio, assets under management (AUM), current price, daily percentage change, relative volume, and 3-year NAV total return. The information helps investors identify diversified opportunities to invest in Vanda Pharmaceuticals with potentially lower risk.
Vanda Pharmaceuticals - Risks Rising, Rewards Dwindling - Why I'm Downgrading To Hold
Vanda Pharmaceuticals is being downgraded to "Hold" due to increasing financial losses, significant cash burn, and uncertainties surrounding its pipeline execution. While Fanapt revenues are growing, the impending patent expiry and decline in Hetlioz sales pose a threat to near-term revenue stability. Although Bysanti and Nereus offer potential upside, their commercial viability and clinical milestones are unproven and have faced delays, with the company's cash potentially depleted by the end of 2027.
Vanda Pharmaceuticals Announces EMA Positive Opinion For Orphan Drug Designation Of Imsidolimab For GPP
Vanda Pharmaceuticals announced that the European Medicines Agency (EMA) has issued a positive opinion for Orphan Drug Designation of Imsidolimab. This designation is for the treatment of Generalized Pustular Psoriasis (GPP). This news was reported by Reuters.
EMA Panel Recommends First EU Orphan Designation for Rare Skin Disease
Vanda Pharmaceuticals announced that the European Medicines Agency (EMA) has issued a positive opinion recommending orphan drug designation for its investigational product, imsidolimab, for the treatment of generalized pustular psoriasis (GPP). This marks the first time the EMA has recognized a GPP treatment with orphan drug designation in the EU, offering benefits like protocol assistance and market exclusivity. This follows similar regulatory recognitions in the US and Japan, and imsidolimab is currently under FDA review with a target action date of December 12, 2026.
Vanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab for Generalized Pustular Psoriasis - A Milestone Recognition of GPP as a Distinct Rare Disease in Europe
Vanda Pharmaceuticals announced that the European Medicines Agency (EMA) has issued a positive opinion recommending orphan drug designation for imsidolimab, their investigational treatment for generalized pustular psoriasis (GPP). This marks the first time a drug for GPP has received such recognition in the EU, highlighting GPP as a distinct rare disease. The designation reinforces imsidolimab's clinical data and addresses an urgent unmet medical need, with the drug also under FDA review in the US.
Vanda Pharmaceuticals to be Primary Sponsor of Mick Schumacher’s INDYCAR Entry for Four Races Beginning in Nashville This Weekend
Vanda Pharmaceuticals will sponsor Mick Schumacher's No. 47 NTT INDYCAR SERIES entry for four races in 2026, featuring their product NEREUS™ for motion sickness prevention. This marks Vanda's first venture into motorsports, adding to their high-profile sports sponsorships. Schumacher, son of Michael Schumacher, is in his first IndyCar season and has shown promise despite being new to the discipline.
Insider Sellers Might Regret Selling Vanda Pharmaceuticals Shares at a Lower Price Than Current Market Value
Insiders of Vanda Pharmaceuticals Inc. sold US$2.8 million worth of stock over the last year at an average price of US$8.20, which is lower than the current share price but still higher than the latest price of US$5.85 after an 11% value drop. Despite the insider selling, the company's founder, Mihael Polymeropoulos, also made the biggest insider purchase of US$42k. Insiders collectively own 4.2% of the company, valued at US$15 million, indicating some alignment with shareholders.
NEREUS™ Powers Forward: Sponsors No. 47 IndyCar Entry, Celebrating 47 Years Since Last New U.S. Motion Sickness Treatment
Vanda Pharmaceuticals Inc. announced that its new medication, NEREUS™ (tradipitant), which prevents motion-induced vomiting, will sponsor the No. 47 entry in the NTT IndyCar Series. This sponsorship highlights NEREUS™ as the first new prescription motion sickness treatment in the U.S. in 47 years. The partnership aims to align the drug's breakthrough innovation with the demands of IndyCar racing.
Vanda Pharmaceuticals To Be Primary Sponsor Of Schumacher’s INDYCAR Entry For Four Races; Schumacher to Pilot the No. 47 NEREUS™ Honda at events in Nashville, Portland, Washington D.C. and Monterey
Vanda Pharmaceuticals will be the primary sponsor for Mick Schumacher's No. 47 NTT INDYCAR SERIES entry in four races in 2026: Nashville, Portland, Washington D.C., and Monterey. Vanda will feature its NEREUS™ product, an oral neurokinin-1 receptor antagonist for preventing motion-induced vomiting, on Schumacher's Honda. This sponsorship marks Vanda's first foray into motorsports, adding to its existing sports sponsorships in ATP, NHL, NBA, WNBA, and college basketball.
Vanda Pharma's new motion sickness drug NEREUS™ sponsors No. 47 IndyCar, marking a 47-year treatment milestone
Vanda Pharmaceuticals announced that its new FDA-approved motion sickness drug, NEREUS™ (tradipitant), will sponsor the No. 47 IndyCar, highlighting it as the first new prescription treatment for motion-induced vomiting in 47 years. This partnership underscores the drug's significance in offering a modern option for millions affected by motion sickness. The sponsorship will be visible at select 2026 IndyCar events, symbolizing innovation and performance.
47 years since the last new motion-sickness treatment, NEREUS will sponsor IndyCar
Vanda Pharmaceuticals announced that its NEREUS™ (tradipitant) medication, the first new prescription treatment for motion-induced vomiting in 47 years, will sponsor the No. 47 entry in the NTT IndyCar Series. This partnership with Rahal Letterman Lanigan Racing highlights NEREUS's breakthrough innovation and will feature branded visibility on the No. 47 IndyCar during select events in 2026. The sponsorship symbolically marks the 47-year gap since the last new motion sickness treatment was introduced in the US.
IndyCar News: Vanda Pharmaceuticals Sponsor Schumacher for Four Races
Vanda Pharmaceuticals, a biopharmaceutical company, announced its sponsorship of Mick Schumacher's No. 47 NTT INDYCAR SERIES entry for four races in 2026. The sponsorship will feature Vanda's NEREUS™ product, an oral neurokinin-1 (NK-1) receptor antagonist for motion-induced vomiting, on Schumacher's Honda. This marks Vanda's first foray into motorsports, adding to its existing sports sponsorships in ATP, NHL, NBA, WNBA, and college basketball.
Has Vanda Pharmaceuticals Finally Found Its Game-Changer with Bysanti
Vanda Pharmaceuticals (VNDA) recently received FDA approval for Bysanti (milsaperidone) for bipolar I disorder and schizophrenia, expanding its psychiatric drug portfolio. Despite an initial sell-off, this approval, coupled with long patent protection, positions Bysanti as a potential significant revenue driver in the competitive $18 billion psychiatric market. However, Vanda faces substantial challenges in commercialization, intense competition, and a current lack of profitability, making it a high-risk, high-reward investment.
Vanda Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Investigational Therapy for Charcot-Marie-Tooth Disease Type 2S
Vanda Pharmaceuticals announced that its investigational therapy for Charcot-Marie-Tooth Disease Type 2S has received Rare Pediatric Disease Designation from the FDA. This news was delivered via Quantisnow's real-time market data platform. The designation highlights the potential of Vanda's therapy for a rare and serious pediatric condition.
Vanda Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Investigational Therapy for Charcot-Marie-Tooth Disease Type 2S
Vanda Pharmaceuticals Inc. announced that the FDA has granted Rare Pediatric Disease Designation to VCA-894A, its investigational therapy for Charcot-Marie-Tooth disease type 2S (CMT2S). This designation acknowledges the significant unmet medical need for this rare, serious, and progressive inherited neurological disorder, which primarily affects children. The company will continue to work closely with the FDA on the development program for VCA-894A, an antisense oligonucleotide therapy targeting a specific genetic variant of CMT2S.
Vanda Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Investigational Therapy for Charcot-Marie-Tooth Disease Type 2S
Vanda Pharmaceuticals (Nasdaq: VNDA) has received FDA Rare Pediatric Disease Designation for VCA-894A, its investigational therapy for Charcot-Marie-Tooth disease type 2S (CMT2S). CMT2S is a rare, severe, and progressive neurological disorder primarily affecting children, for which there are limited treatment options. This designation aims to accelerate the development of VCA-894A, which targets a unique genetic variant of CMT2S.
Vanda Pharmaceuticals (VNDA) Receives FDA Rare Pediatric Disease Designation
Vanda Pharmaceuticals (VNDA) has received FDA Rare Pediatric Disease Designation for VCA-894A, an experimental therapy for Charcot-Marie-Tooth disease, axonal, type 2S (CMT2S). This designation is a critical step for addressing the rare genetic disorder and could lead to a priority review voucher. Despite challenges in profitability and recent insider selling, the company holds a GF Score of 72/100, indicating potential for growth in the rare disease market.
VNDA Stock Gains After-Hours As FDA Grants Rare Pediatric Disease Designation For Experimental Therapy
Vanda Pharmaceuticals (VNDA) saw its stock rise after-hours following the FDA's granting of Rare Pediatric Disease Designation for VCA-894A, its experimental treatment for Charcot-Marie-Tooth disease type 2S. This designation could make Vanda eligible for a priority review voucher, speeding up market access for the therapy which addresses a serious genetic nerve condition primarily affecting children. The company already has approved products like Fanapt and Hetlioz, with other therapies awaiting FDA approval or preparing for commercial launch.
Vanda Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Investigational Therapy for Charcot-Marie-Tooth Disease Type 2S
Vanda Pharmaceuticals has received FDA Rare Pediatric Disease Designation for VCA-894A, an investigational antisense oligonucleotide therapy for Charcot-Marie-Tooth disease type 2S (CMT2S). CMT2S is a rare, severe inherited neurological disorder primarily affecting children, leading to progressive muscle weakness and loss of motor function. This designation acknowledges the significant unmet medical need and may qualify Vanda for a priority review voucher upon approval, expediting the development of this potentially transformative therapy.
Vanda Pharmaceuticals updates investors on business outlook as shares trade in the U.S. market
Vanda Pharmaceuticals, a U.S.-based biopharmaceutical company, continues to develop treatments in neurology, psychiatry, and sleep medicine, with its shares trading on the American market. The company focuses on specialty prescription drugs, generating revenue from approved therapies while investing in R&D, and investors are keenly watching its pipeline, regulatory progress, and clinical milestones. The article highlights the importance of market broadness, R&D balance between late-stage and early-stage programs, and the impact of payer negotiations and reimbursement decisions on its revenue.
VNDA Stock Gains After-Hours As FDA Grants Rare Pediatric Disease Designation For Experimental Therapy
Vanda Pharmaceuticals (VNDA) saw its stock gain 1% after-hours following the FDA's decision to grant Rare Pediatric Disease Designation to its experimental therapy, VCA-894A, for Charcot-Marie-Tooth disease type 2S (CMT2S). This designation could make Vanda eligible for a priority review voucher, speeding up market access for their treatment for the rare genetic nerve disorder. The company also anticipates upcoming FDA decisions for imsidolimab and a commercial launch for BYSANTI later in 2026.
VNDA - Vanda Pharmaceuticals Inc Volatility & Greeks
This article provides a detailed overview of Vanda Pharmaceuticals Inc. (VNDA), including its latest stock performance, key financial metrics, volatility, and options Greeks. It covers market capitalization, recent earnings data, insider and institutional ownership, and various performance indicators.
McDermott Represents Vanda Pharmaceuticals Inc. on Acquisition of PONVORY®
McDermott Will & Emery represented Vanda Pharmaceuticals Inc. in its acquisition of US and Canadian rights to PONVORY®, a treatment for relapsing forms of multiple sclerosis. The McDermott deal team was led by Kristian Werling with support from numerous other attorneys. This acquisition allows Vanda to expand its portfolio in the biopharmaceutical sector.
Here’s Why H.C. Wainwright Remains a Buy on Vanda Pharmaceuticals (VNDA)
H.C. Wainwright has reiterated a Buy rating for Vanda Pharmaceuticals (VNDA) with a $21 price target, following an update on the company's FDA approval process for HETLIOZ as a jet lag treatment. The FDA has granted Vanda a formal hearing, a rare event, to discuss the drug's approval after an initial refusal. This hearing, expected before year-end, could allow Vanda to generate branded prescription sales for a new jet lag indication, largely protected from generic competition.
Vanda Pharmaceuticals Inc.(NasdaqGM:VNDA) dropped from Russell 2000 Defensive Index
Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA) has been removed from the Russell 2000 Defensive Index. This news comes amidst other recent updates for the biopharmaceutical company, including its Q1 2026 earnings call, raising its full-year 2026 revenue guidance, and the U.S. commercial availability of its new motion sickness drug, Nereus. Vanda Pharmaceuticals is actively involved in developing and commercializing therapies for various unmet medical needs, with a pipeline that includes drugs for schizophrenia, sleep-wake disorders, multiple sclerosis, and motion sickness.
Vanda Pharmaceuticals Inc.(NasdaqGM:VNDA) dropped from Russell 2000 Value-Defensive Index
Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA) has been removed from the Russell 2000 Value-Defensive Index. This announcement follows several recent company updates, including its Q1 2026 earnings call, raised revenue guidance, and the U.S. launch of its motion sickness drug Nereus. The biopharmaceutical company remains focused on developing and commercializing therapies for various medical needs.
